Loading quotes...

Forecast

The analysts' average price target is €11.36 (+55.19%). The median is €7.69 (+5.05%).

Buy	8
Hold	6
Sell	2

News Go to news feed

Y-mAbs Therapeutics surges 103% after acquisition by SERB Pharmaceuticals

Shares of Y-mAbs Therapeutics jumped 103% after SERB Pharmaceuticals announced it would acquire the company for approximately $412 million in cash. SERB is offering $8.60 per share, representing a premium of about 105% over the previous closing price, and will add the FDA-approved drug DANYELZA to its portfolio. The transaction was unanimously approved by the Y-mAbs board of directors and is expected to close by the fourth quarter of 2025. » More on de.investing.com
Y-mAbs Therapeutics receives shareholder approval for all AGM proposals and beats quarterly expectations

Y-mAbs Therapeutics received shareholder approval for all three proposals at its annual general meeting, including the election of David N. Gill as Class I Director. The company exceeded earnings expectations in the first quarter of 2025, achieving an 8% year-over-year increase in revenue driven by international sales. Analysts maintained their buy recommendation for Y-mAbs, citing progress in SADA technology and the drug pipeline. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2022, Y-MABS THERAP. DL-,0001 has already paid €0.20 in dividends. The last payout was in June 2022.

Financials

In the last quarter, Y-MABS THERAP. DL-,0001 had revenue of €16.57M and net profit of -€2.75M

(EUR)	June 2025	YoY
Revenue	16.57M	-
Gross profit	14.31M	-
Net profit	-2.75M	-
EBITDA	-2.7M	-

Fundamentals

Metric	Value
Market capitalization	€349.6M
Number of shares	45.44M
52-week high/low	€14.40 - €3.17
Dividends	No
Beta	0.53
P/E ratio	-12.85
PEG ratio	-98.21
P/B ratio	4.15
P/S ratio	4.46

Company profile

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.